Aim: In this study, the effect of specific or selective adsorption of inflammatory mediators on endothelial activation was assessed. Methods: Conditioned medium was obtained by stimulation of monocytic THP-1 cells with lipopolysaccharide and treated either with an adsorbent specific for tumour necrosis factor-α or with an albumin-coated polystyrene-divinylbenzene copolymer which selectively binds a range of cytokines. Thereafter, the conditioned medium was applied to endothelial cells in culture. Results: Adsorption of inflammatory mediators resulted in significantly decreased endothelial cell activation, as shown by reduced interleukin (IL)-6 and IL-8 secretion from endothelial cells as well as reduced surface expression of the adhesion molecules intercellular adhesion molecule-1 and E-selectin. The effect was more pronounced the earlier the mediator modulation was performed. Conclusion: Adsorptive modulation of inflammatory mediators dampens endothelial cell activation and may thus be beneficial as supportive therapy in sepsis.

Keywords:
Adsorption, Polymers, Blood purification, Endothelial cell activation, Sepsis
1.
Aird WC: Endothelium in health and disease. Pharmacol Rep 2008;60:139–143.
2.
Hack CE, Zeerleder S: The endothelium in sepsis: source of and a target for inflammation. Crit Care Med 2001;29:S21–S27.
3.
Matsuda N, Hattori Y: Vascular biology in sepsis: pathophysiological and therapeutic significance of vascular dysfunction. J Smooth Muscle Res 2007;43:117–137.
4.
Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303–1310.
5.
Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, Ramsay G, Zimmerman JL, Vincent JL, Levy MM: Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004;32:858–873.
6.
Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut JF, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent JL; International Surviving Sepsis Campaign Guidelines Committee; American Association of Critical-Care Nurses; American College of Chest Physicians; American College of Emergency Physicians; Canadian Critical Care Society; European Society of Clinical Microbiology and Infectious Diseases; European Society of Intensive Care Medicine; European Respiratory Society; International Sepsis Forum; Japanese Association for Acute Medicine; Japanese Society of Intensive Care Medicine; Society of Critical Care Medicine; Society of Hospital Medicine; Surgical Infection Society; World Federation of Societies of Intensive and Critical Care Medicine: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008;36:296–327.
7.
Sarangi PP, Lee HW, Kim M: Activated protein C action in inflammation. Br J Haematol 2010;148:817–833.
8.
Marshall JC: Such stuff as dreams are made on: mediator-directed therapy in sepsis. Nat Rev Drug Discov 2003;2:391–405.
9.
Remick DG: Cytokine therapeutics for the treatment of sepsis: why has nothing worked? Curr Pharm Des 2003;9:75–82.
10.
Bellomo R, Honore PM, Matson J, Ronco C, Winchester J: Extracorporeal blood treatment methods in SIRS/sepsis. Int J Artif Organs 2005;28:450–458.
11.
Falkenhagen D, Strobl W, Vogt G, Schrefl A, Linsberger I, Gerner FJ, Schoenhofen M: Fractionated plasma separation and adsorption system: a novel system for blood purification to remove albumin bound substances. Artif Organs 1999;23:81–86.
12.
Cruz DN, Perazella MA, Bellomo R, de Cal M, Polanco N, Corradi V, Lentini P, Nalesso F, Ueno T, Ranieri VM, Ronco C: Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review. Crit Care 2007;11:R47.
13.
Ronco C, Brendolan A, Lonnemann G, Bellomo R, Piccinni P, Digito A, Dan M, Irone M, La Greca G, Inguaggiato P, Maggiore U, De Nitti C, Wratten ML, Ricci Z, Tetta C: A pilot study of coupled plasma filtration with adsorption in septic shock. Crit Care Med 2002;30:1250–1255.
14.
Schefold JC, von Haehling S, Corsepius M, Pohle C, Kruschke P, Zuckermann H, Volk HD, Reinke P: A novel selective extracorporeal intervention in sepsis: immunoadsorption of endotoxin, interleukin 6, and complement-activating product 5a. Shock 2007;28:418–425.
15.
Weber V, Hartmann J, Linsberger I, Falkenhagen D: Efficient adsorption of tumor necrosis factor with an in vitro set-up of the microspheres-based detoxification system. Blood Purif 2007;25:169–174.
16.
Weber V, Linsberger I, Ettenauer M, Loth F, Hoyhtya M, Falkenhagen D: Development of specific adsorbents for human tumor necrosis factor-alpha: influence of antibody immobilization on performance and biocompatibility. Biomacromolecules 2005;6:1864–1870.
17.
Schildberger A, Rossmanith E, Weber V, Falkenhagen D: Monitoring of endothelial cell activation in experimental sepsis with a two-step cell culture model. Innate Immun 2010;16:278–287.
18.
Kellum JA, Song M, Venkataraman R: Hemoadsorption removes tumor necrosis factor, interleukin-6, and interleukin-10, reduces nuclear factor-kappaB DNA binding, and improves short-term survival in lethal endotoxemia. Crit Care Med 2004;32:801–805.
19.
Tetta C, Cavaillon JM, Schulze M, Ronco C, Ghezzi PM, Camussi G, Serra AM, Curti F, Lonnemann G: Removal of cytokines and activated complement components in an experimental model of continuous plasma filtration coupled with sorbent adsorption. Nephrol Dial Transplant 1998;13:1458–1464.
20.
Cantaluppi V, Weber V, Lauritano C, Figliolini F, Beltramo S, Biancone L, De Cal M, Cruz D, Ronco C, Segoloni GP, Tetta C, Camussi G: Protective effect of resin adsorption on septic plasma-induced tubular injury. Crit Care 2010;14:R4.
21.
Bellomo R, Tetta C, Ronco C: Coupled plasma filtration adsorption. Intensive Care Med 2003;29:1222–1228.
22.
Formica M, Olivieri C, Livigni S, Cesano G, Vallero A, Maio M, Tetta C: Hemodynamic response to coupled plasma filtration-adsorption in human septic shock. Intensive Care Med 2003;29:703–708.
23.
Ronco C, Brendolan A, d’Intini V, Ricci Z, Wratten ML, Bellomo R: Coupled plasma filtration adsorption: rationale, technical development and early clinical experience. Blood Purif 2003;21:409–416.
24.
DiLeo MV, Fisher JD, Burton BM, Federspiel WJ: Selective improvement of tumor necrosis factor capture in a cytokine hemoadsorption device using immobilized anti-tumor necrosis factor. J Biomed Mater Res B Appl Biomater 2011;96:127–133.
25.
Hamaguchi E, Takamura T, Shimizu A, Nagai Y: Tumor necrosis factor-alpha and troglitazone regulate plasminogen activator inhibitor type 1 production through extracellular signal-regulated kinase- and nuclear factor-kappaB-dependent pathways in cultured human umbilical vein endothelial cells. J Pharmacol Exp Ther 2003;307:987–994.
26.
Orbe J, Chorda C, Montes R, Paramo JA: Changes in the fibrinolytic components of cultured human umbilical vein endothelial cells induced by endotoxin, tumor necrosis factor-alpha and interleukin-1alpha. Haematologica 1999;84:306–311.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.